ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone33-4-78-74-44-38
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees172
Next Earnings DateN/A
OptionableNot Optionable
Erytech Pharma (NASDAQ:ERYP) Frequently Asked Questions
What is Erytech Pharma's stock symbol?
Erytech Pharma trades on the NASDAQ under the ticker symbol "ERYP."
What price target have analysts set for ERYP?
2 Wall Street analysts have issued twelve-month target prices for Erytech Pharma's shares. Their forecasts range from $13.00 to $13.00. On average, they expect Erytech Pharma's stock price to reach $13.00 in the next year. This suggests a possible upside of 150.0% from the stock's current price. View Analyst Price Targets for Erytech Pharma.
What is the consensus analysts' recommendation for Erytech Pharma?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Erytech Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Erytech Pharma.
Has Erytech Pharma been receiving favorable news coverage?
Media coverage about ERYP stock has been trending very negative this week, InfoTrie reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Erytech Pharma earned a coverage optimism score of -3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Erytech Pharma.
Are investors shorting Erytech Pharma?
Erytech Pharma saw a increase in short interest in October. As of October 31st, there was short interest totalling 1,300 shares, an increase of 18.2% from the September 30th total of 1,100 shares. Based on an average daily trading volume, of 500 shares, the short-interest ratio is currently 2.6 days. Approximately 0.0% of the shares of the company are sold short. View Erytech Pharma's Current Options Chain.
Who are some of Erytech Pharma's key competitors?
Some companies that are related to Erytech Pharma include Tcr2 Therapeutics (TCRR), Cellular Biomedicine Group (CBMG), PDL BioPharma (PDLI), Harpoon Therapeutics (HARP), CASI Pharmaceuticals (CASI), Gritstone Oncology (GRTS), Compugen (CGEN), Eiger Biopharmaceuticals (EIGR), Scholar Rock (SRRK), ADMA Biologics (ADMA), Sutro Biopharma (STRO), BioCryst Pharmaceuticals (BCRX), LogicBio Therapeutics (LOGC), La Jolla Pharmaceutical (LJPC) and X4 Pharmaceuticals (XFOR).
What other stocks do shareholders of Erytech Pharma own?
Who are Erytech Pharma's key executives?
Erytech Pharma's management team includes the folowing people:
- Mr. Gil Beyen, Chairman & CEO (Age 57)
- Mr. Jérôme Bailly Pharm.D., VP, Director of Pharmaceutical Operations & Deputy GM (Age 40)
- Mr. Eric Soyer, CFO & COO (Age 53)
- Dr. Alexander Scheer, Chief Scientific Officer (Age 57)
- Naomi Eichenbaum, Director Investor Relations
When did Erytech Pharma IPO?
(ERYP) raised $125 million in an initial public offering (IPO) on Friday, November 10th 2017. The company issued 5,300,000 shares at $23.00-$24.00 per share. Jefferies, Cowen and Oddo BHF acted as the underwriters for the IPO and JMP Securities was co-manager.
How do I buy shares of Erytech Pharma?
Shares of ERYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Erytech Pharma's stock price today?
One share of ERYP stock can currently be purchased for approximately $5.20.
How big of a company is Erytech Pharma?
Erytech Pharma has a market capitalization of $93.29 million. The company earns $-45,140,000.00 in net income (profit) each year or $2.44 on an earnings per share basis. Erytech Pharma employs 172 workers across the globe.View Additional Information About Erytech Pharma.
What is Erytech Pharma's official website?
How can I contact Erytech Pharma?
Erytech Pharma's mailing address is 60 AVENUE ROCKEFELLER BATIMENT ADENINE, LYON I0, 69008. The company can be reached via phone at 33-4-78-74-44-38 or via email at [email protected]
MarketBeat Community Rating for Erytech Pharma (NASDAQ ERYP)
MarketBeat's community ratings are surveys of what our community members think about Erytech Pharma and other stocks. Vote "Outperform" if you believe ERYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ERYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
